With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

Wells Fargo lowered the firm’s price target on Concentra (CON) to $25 from $27 and keeps an Overweight rating on the shares. The firm is also ...

Concentra®, the nation’s leader in occupational medicine, today announced the acquisition of the assets of Physicians Health ...

Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

Rating for Concentra Group jumped into a higher percentile Friday, as it got a lift from 68 to 76. Please watch the video at ...

Concentra acquired five clinics in Miami-Dade County. The clinics specialize in work injury care and drug testing. OM ...

ADDISON, Texas, March 10, 2025--Concentra®, the nation’s leader in occupational medicine, today announced the acquisition of the assets of Physicians Health Center (PHC) and OM Management (OMM).

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

BofA raised the firm’s price target on Concentra (CON) to $26 from $25 and keeps a Buy rating on the shares. Q4 results were in line the ...